Fairmont Chateau Whistler Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
- Meeting Program
- Meeting Summary
- Abstract Information
- Registration Information
- Scholarships / Awards
- Lodging / Hotels
- Travel / Transportation
- Conference Location
- Things to Do
- Services
- My Account
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
This meeting is part of the Global Health Series

Twitter hashtag for this meeting: #KShivvax
HIV Vaccines (X7)
joint with the meeting on Functional Cures and the Eradication of HIV (X8)Scientific Organizers: Nicole A. Doria-Rose, Thumbi Ndung'u and Gunilla Karlsson Hedestam
March 24—28, 2019
Fairmont Chateau Whistler, Whistler, British Columbia, Canada
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Deadline: Oct 23, 2018 [details]
Scholarship Deadline: Dec 5, 2018 [details]
Discounted Abstract Deadline: Dec 5, 2018 [details]
Abstract Deadline: Dec 18, 2018 [details]
Discounted Registration Deadline: Jan 24, 2019 [details]
If you have missed a deadline due to the US government shutdown, please contact our office.
Click here to view Cancellation Policy
Discounted Abstract Deadline: December 5, 2018
*All deadlines end at 11:59 PM US Mountain Standard TimeAbstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register
Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract early allows us to:
- submit your abstract to organizers to be considered for a short talk
- accept your abstract online
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
(The Abstract Deadline: is December 18, 2018)
Global Health Travel Award Deadline: October 23, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Details:
You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline
and complete the other required steps (verify your contact information and submit a recommendation letter)
to be considered for a travel award.
Click here to learn more about Global Health Travel Awards.
Scholarship Deadline: December 5, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Details:
You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.
Abstract Deadline: December 18, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register
Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract by the Abstract Deadline allows us to:
- submit your abstract to organizers to be considered for a short talk
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.
(Discounted Abstract Deadline: is December 5, 2018)
Discounted Registration Deadline: January 24, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Registration Fee: 945.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 720.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
After the Discounted Registration Deadline:
Registration Fee: 1145.00 USD*
Student Registration Fee: 920.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
Registration spaces are limited and may fill prior to discounted registration deadline.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, March 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 29 in order to fully experience the meeting.
SUNDAY, MARCH 24
Challenges and Opportunities for Antibody-Based HIV Vaccines
New Insights into the Extent and Dynamics of the Latent Reservoir
Registered attendees can view abstracts starting on 02/24/2019
Engineering Antibodies to Combat HIV/AIDS
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy
Short Talk: Long-term SHIV-AD8 remission with AAV-expressed eCD4-Ig
Short Talk: Distribution and localization of I.V. injected VRC01 and VRC01-LS in the in vivo Rhesus Macaque Model
Oral Immunization with Native-Like HIV-1 Trimers Elicits Systemic Immune Responses and Cross-Clade Reactive Anti-V1V2 Antibodies
Tight Control of SHIV Challenge in Macaques with Vaccine-Induced Neutralizing and Non-Neutralizing Anti-V2 Antibodies
Induction of Cross-Clade Heterologous Tier-2 HIV-1 Neutralizing Antibodies by an mRNA-Based Vaccine in Macaques
A Vaccine Targeting HIV Maturation Protects Cynomolgus Monkeys Against Vaginal SIVmac251 Acquisition
Anti-CTLA-4 Therapy Enhances Vaccine Immunogenicity but not Efficacy Against Simian Immunodeficiency Virus Challenge in Rhesus Macaques
Slow Delivery Immunization Enhances Germinal Center and Neutralizing Antibody Responses via Modulation of Immunodominance
SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding
A Role for MAdCAM and Retinoic Acid in Establishing Viral Replication in Gut Associated Lymphoid Tissues
Development of Monoclonal Antibodies from Elite Controllers to Target the HIV Reservoir
Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells
CD56neg NK Cells Have Increased Functional Response to CD16 Stimulation in Chronic HIV
PD-1/PD-L1 Interaction Modulates HIV-1 Transcription in Lymph Nodes of Treated Aviremic Individuals
A Genetically Encoded Switch to Monitor HIV Infection and Latency within Humanized Mice Reveals HIV-Susceptibility Associated with Diverse T Cell Transcriptional States
Paired Host-Virus Single Cell Genomics Identifies Cell Types Harboring Virus in Humans and Non-Human Primates
CD32+CD4+ T cells are highly enriched in HIV DNA
Registered attendees can view abstracts starting on 02/24/2019
Short Talk: B Cell Priming from RV144 Vaccination Impacts Post-Infection Antibody Responses
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies
T-Cell Vaccine Trials for HIV
Short Talk: Human Memory NK Cells Are Potently Induced by HIV and HIV Vaccines
Registered attendees can view abstracts starting on 02/24/2019
Defining Conserved Correlates of Humoral Immune Protection Against SIV/SHIV
Targeting B Lymphocytes to Control HIV-1
Neutralizing Antibodies, Vaccines and Long-Term Control of HIV Infection
Short Talk: Complement Activation at the Surface of HIV-1-Infected Cells
Short Talk: Tissue Seeding Determines Setpoint and Drives SHIV Pathogenesis in Infant Macaques
Registered attendees can view abstracts starting on 02/24/2019
Antibody Germline Genes and Impact on Vaccine Responses
In Vivo Lineage Tracing of Antigen-Specific B Cells After Vaccination
Short Talk: High-Throughput Mapping of B-Cell Receptor Sequence to Antigen Specificity
Short Talk: Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies
Characterization of Antigen Specific Memory B Cells Following Vaccination
The Antigen-Specific Human Naive B Cell Repertoire: A Starting Point for Vaccine Responses
Short Talk: Bcl-6/Bcl-xL B Cell Immortalization for Antibody Discovery in Vaccination and Chronic Infection
Registered attendees can view abstracts starting on 02/24/2019
Long Non-Coding RNAs Involved in HIV Latency and Reactivation
CRISPR Based Characterizing of Latency-Associated Pathways
Signaling Pathways Controlling HIV Reactivation from Latency
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate
Short Talk: A Functional Map of HIV-Host Interactions in Primary Human CD4+ T cells
Short Talk: Target HIV Viral Release Pathway as A New Antiviral Strategy
Short Talk: Whole Exome Sequencing Identifies SNVs and Indels Associated with HIV+ Elite and Viremic Control
Click here for more information
Registered attendees can view abstracts starting on 02/24/2019
Broadly Neutralizing Antibodies: Lessons from Natural Infection
Short Talk: CH505 Transmitted/Founder Envelope Elicits Tier 2 Neutralizing Antibodies Against the CD4 Binding and V1V2-Glycan Sites during Human Infection and Macaque Vaccination
Inference of the VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
Fast and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage
Short Talk: Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-Human Primates
Epigenetic Regulation of HIV Transcription
HIV-Host Interactions at the Genomic Level
Discovery & Characterization of a Virus-Intrinsic HIV Latency Circuit
Short Talk: Identification of Novel Pathways that Regulate HIV Transcription using an Unbiased Functional Screen
Short Talk: Investigation of Potential Roles for lncRNAs in Establishment and Maintenance of HIV Latency
Registered attendees can view abstracts starting on 02/24/2019
Treatment in Acute Infection: Lessons from the FRESH Cohort
Therapeutic Vaccines after Early ART: Impact on Viral Load Control Post Interruption
Therapeutic Vaccines after Early ART: Impact on Reservoir
Reversing HIV Latency with AKT/mTOR Activators
Short Talk: Combining a TLR7 Agonist with a Heterologous Virus-Like Particle for Potent and Specific Latency Reversal in Patient Samples during Stable cART
Short Talk: HIV Gag and Env Conserved Element CE DNA Vaccine Elicits Broad Cytotoxic T Cell Responses Targeting Subdominant Epitopes
Click here for more information
Isotype-Dependent Protection Against Mucosal HIV Transmission in Humanized Mouse Models
Autoreactivity Mediated by Total IgG Is not Associated with the Development of Neutralization Breadth
An MPER Antibody that Neutralizes HIV Using Recognition Properties and Germline Genes Shared Among Donors
Antibody Fab Elbow Mutations Modulate Interdomain Flexibility and Dynamics of HIV-1 Broadly Neutralizing Antibodies
Antigenic Conservation of the V2 Apex Among Primate Lentiviruses
Structural Basis for Potent Tier 2 Autologous Neutralization Elicited by Vaccination
An Asymmetric Opening of HIV-1 Env Is Required for Anti-Cluster A Antibody Binding
Electron Microscopic Characterization of HIV Envelope in Detergent Micelles, Lipid Bicelles and Nanodiscs
Registered attendees can view abstracts starting on 02/24/2019
Vaccine-Elicited T Cells in Clinical Trials
Short Talk: Ad5/HIV Vaccines Induce CD8+ T Cells with Insufficient Avidity to Kill HIV-Infected CD4+ T Cells
Tissue Resident T Cells
Unconventional T Cells: Potential for Induction by Vaccination
Short Talk: Longitudinal Dynamics of Follicular CD4+ T Cells in Acute SIV Infection
Registered attendees can view abstracts starting on 02/24/2019
Attacking Latent Reservoirs
In vivo Gene Therapy and Nano-medicine to Treat HIV
Short Talk: RNA-Directed Epigenetic Silencing Protects Humanized Mice during HIV Challenge
Short Talk: The HIV-1 Antisense Transcript Ast Induces Viral Latency via Several Silencing Pathways
Modified HIV Trimers to Elicit Cross-Neutralizing Responses
Short Talk: Stabilized HIV-1 Clade C Envelope Trimers with Increased Stability and Preferential Antigenic Properties In Vitro and In Vivo
Native Glycan Shield is Important for Inducing Immune Responses that Neutralize Diverse Tier-2 Viruses in Sequential HIV-1 Env Trimer Immunization
Short Talk: Germline VRC01 Antibody Recognition of a Modified Clade C HIV-1 Envelope Trimer and a Glycosylated HIV-1 gp120 Core
In vivo Fate of Env and Early Responses upon Immunization
Designing and Building the Next Generation of Vaccine Adjuvants
Short Talk: Development of Self-assembling Nanoparticle Systems for Presentation of HIV Env Trimers
Progress Towards Targeting and Eradication of HIV in Models and Man
Understanding Natural Variation in HIV Transcription on Antiretroviral Therapy: New Approaches to Reverse HIV Latency
Latency and Viral Infection in Pediatrics
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs (‘ImmTAVs’) to Clear HIV Infection
Short Talk: 3D Genome Conformation is the Major Determinant of HIV-1 Integrational Hot-Spots
Short Talk: In Vitro, Ex Vivo and In Vivo Analysis of Benzotriazine Derivatives as Latency Reversing Agents
Short Talk: Latency Reversing Agents Induce Differential Responses in Distinct Memory CD4+ T Cell Subsets
Filgotinib, a Janus Kinase Inhibitor, Suppresses HIV-1 Expression and T Cell Activation
A Novel Small Molecule Modulating BRD4 to Epigenetically Suppress HIV
A highly Potent and Safe Allosteric HIV-1 Integrase Inhibitor: Virological, Molecular, and Preclinical Characterization of STP0404
Single-Cell Sequencing Reveals Transcriptome and Surfaceome Signatures of HIV Latently-Infected Cells
Nanoparticle Delivery of Epigenetic Silencing siRNA to the Nucleus of HIV-1 Infected Cells
Splicing Factor 3B Subunit 1 Interacts HIV Tat and can be Targeted to Prevent Viral Transcription and Reactivation from Latency
HIV Cure Strategies with Interferon Alpha Subtype 14 in HIV-1 Infected Humanized Mice
In Vivo Effects of Romidepsin in the Bcn02 Kick&Kill Trial for Hiv Remission
Registered attendees can view abstracts starting on 02/24/2019
Impact of Immunogen Design and Replication on Pre-Clinical and Clinical Immunogenicity
Steps Towards a Fusion Peptide-Based Vaccine
Advancing an HIV Vaccine Candidate through the Development Pipeline: A View from Industry
Translation of Multiple Products from Discovery to the Clinic: The View from a Product Development Center at a Non-Profit Organization
Registered attendees can view abstracts starting on 02/24/2019
Genome Engineering Strategies to Generate HIV Resistant Cells
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells
Flare, Flush, Excise, or Kill; Possible Pathways towards a Functional Cure for HIV
Short Talk: Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates
Registered attendees can view abstracts starting on 02/24/2019
Registered attendees can view abstracts starting on 02/24/2019
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
![]() |
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
![]() |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |